Notification of Drug Policy Revisions Effective January 1, 2024 (Posted November 1, 2023)
| Medical Drug Policy Name | Revised Criteria |
|---|---|
| Fecal Microbiota, Live – jslm (Rebyota) Notification (PDF) | Added requirement that positive stool test for Clostridioides difficile toxin or toxigenic Clostridioides difficile must be within the past 30 days. Policy notification given 11/1/2023 for effective date 1/1/2024. |
| Tezepelumab-ekko (Tezspire) Notification (PDF) | Added requirement for use of the self-administered product unless certain criteria are met. Removed step requirements through Dupixent, Fasenra, Nucala, and Xolair for associated indications. Minor adjustments made to formatting with no change to policy intent. Policy notification given 11/1/2023 for effective date 1/1/2024. |
Blue Cross and Blue Shield of North Carolina does not discriminate on the basis of race, color, national origin, sex, age or disability in its health programs and activities. Learn more about our non-discrimination policy and no-cost services available to you.
Information in other languages: Español 中文 Tiếng Việt 한국어 Français العَرَبِيَّة Hmoob ру́сский Tagalog ગુજરાતી ភាសាខ្មែរ Deutsch हिन्दी ລາວ 日本語
© 2024 Blue Cross and Blue Shield of North Carolina. ®, SM Marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield plans. All other marks and names are property of their respective owners. Blue Cross and Blue Shield of North Carolina is an independent licensee of the Blue Cross and Blue Shield Association.